Inadequate Data for Safe Use of Pre-filled Syringe (Needle Safety Guard)
Severity: criticalThe sponsor has not provided adequate data to support the safe use of the proposed product, ZIMHI, in community settings. The current device design raises safety concerns as intended users may have difficulty deploying the needle safety guard, leading to a risk of needlestick injury and potential transmission of bloodborne pathogens, especially for laypersons.
Recommended response: Modify the device to include an automatically deploying needle safety element. Submit an updated comprehensive use-related risk analysis (URRA) and the results of a human factors (HF) validation study. Consider submitting the HF validation study protocol for agency feedback (60-day review period).
Insufficient Statistical Justification and Evidence for Device Performance
Severity: majorThe submission contains scientific flaws in the statistical analysis and evidence for device malfunction mitigations. Issues include combining data from multiple sources without clear linkage to failure rates, unclear relation of Cpk values to stated failure rates, lack of failure rate data for basic events, absence of normality tests for Cpk data, invalid Cpk analysis for non-normal data, and unsubstantiated failure rates due to lack of process validation evidence.
Recommended response: Provide an analysis using a single failure rate for each failure mode, clearly linking Cpk values to failure rates. Provide failure rate data for basic events. Conduct normality tests for Cpk data and provide a valid statistical analysis for non-normal data. Provide evidence of validated assembly processes and equipment. Revise the Fault Tree Analysis considering changes to the needle safety device.
Inadequate Verification and Validation Testing for Sharps Injury Prevention
Severity: majorThe evidence provided to support claimed device malfunction mitigations, particularly for sharps injury prevention features, contains consistent scientific flaws. These include a lack of detailed test methods, insufficient explanation of method adequacy, absence of sample sizes and justification, incomplete data analysis (e.g., normality), and non-representative samples (e.g., accelerated aging not matching shelf-life, use of alpha build components).
Recommended response: Demonstrate that the device functions safely under worst-case, reasonably conceivable conditions (sterile, at expiry, following shipping challenge) with adequate testing. Review FDA guidances on non-clinical bench performance and appropriate use of voluntary consensus standards. Provide data verifying and validating the needle safety function per the 'Medical Devices with Sharps Injury Prevention Features' guidance.
